With Big Pharma under the gun, changes in top management should be no surprise.
Still, the number of new faces is impressive (see Exhibit 1 for a review of what we think are the biggest changes). By early next year, the industry will have...
Big Pharma is under the gun, with plenty of top management changes. By early next year, the industry will have seen five new CEOs; five new CFOs; a handful of changes in the top R&D spots, and a couple of new commercial bosses, all announced since the beginning of 2007 (an exhibit charts the changes). Of the sixteen job changes, six came about because the predecessor in the job was, if not outright fired, at least pressured to leave. But how much change are we really going to see?
With Big Pharma under the gun, changes in top management should be no surprise.
Still, the number of new faces is impressive (see Exhibit 1 for a review of what we think are the biggest changes). By early next year, the industry will have...
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.